Business Context and Reporting Period
This Form 8-K filing by Autolus Therapeutics Plc (AUTL) reports a change in the registrant's certifying accountant. The report date is April 14, 2026, covering events occurring on that date. The company is incorporated in England and Wales and lists its American Depositary Shares on The Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Dismissal of Auditor: On April 14, 2026, the Audit Committee dismissed Ernst & Young LLP (UK) ("EY UK") as the independent registered public accounting firm.
- Appointment of New Auditor: On April 14, 2026, the Audit Committee appointed Ernst & Young LLP (US) ("EY US") as the new independent registered public accounting firm, effective immediately for the fiscal year ending December 31, 2026.
- Audit History: The filing states there were no disagreements or reportable events with EY UK during the fiscal years ended December 31, 2025, and 2024, except for previously disclosed material weaknesses in internal controls over financial reporting as of March 31, 2024.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the historical material weaknesses in internal controls over financial reporting, which were noted in the 2024 10-Q filing. The company confirmed that the audit reports for the two most recent fiscal years did not contain adverse opinions, disclaimers, or qualifications.
Investor Verification Checklist
- Verify the status of the previously disclosed material weaknesses in internal controls over financial reporting.
- Confirm the transition timeline and scope of work between EY UK and EY US.
- Review the letter from EY UK (Exhibit 16.1) to ensure no undisclosed disagreements exist.
- Monitor upcoming filings for the rationale behind switching from the UK to the US entity of the same accounting firm.